|Videos|December 15, 2017

Glasdegib Active in Heavily Pretreated Myelofibrosis

Author(s)Aaron Gerds, MD

This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.

In this video, Aaron Gerds, MD, of the Cleveland Clinic in Ohio, discusses the phase I portion of a phase I/II trial testing the smoothened (SMO) inhibitor glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.

Gerds gave a presentation on this study (abstract 258) at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

September 28th, 2026

Pirtobrutinib Earns Approval in China for CLL/SLL Across All Therapy Lines

Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

September 24th, 2026

Anselamimab’s Kappa Subgroup Signal Could Reshape Anti-Fibril Therapy in AL Amyloidosis

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

September 23rd, 2026

Defining the Role of Bispecifics in Relapsed Waldenström Macroglobulinemia

Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.

$An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.$

September 22nd, 2026

Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS

An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.

The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.

September 22nd, 2026

Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera

The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.

Trending on CancerNetwork

BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma

Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer

Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care

Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer

SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery